Bristol-Myers Squibb reports strong new product growth in Q4 2025 earnings call

finance.yahoo.com

Bristol-Myers Squibb reported strong growth from new products, offsetting declines in older ones. The company anticipates significant 2026 catalysts, including upcoming data for six products and over ten Phase 3 readouts, with potential upside in Celmat, Ad Milbin, and Milvexian. Eliquis shows strong performance despite pricing adjustments, and business development remains a priority, focusing on existing therapeutic areas.


With a significance score of 1.2, this news ranks in the top 50% of today's 30748 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: